癌症相关成纤维细胞CAF外泌体蛋白在食管鳞状细胞癌中的预后和免疫作用
核心信息
- 论文英文标题: Prognostic and immunological role of cancer-associated fibroblasts-derived exosomal protein in esophageal squamous cell carcinoma
- 期刊: Int Immunopharmacol
- 发表年份: 2023
- DOI: 10.1016/j.intimp.2023.110837
- PMID/PMCID: 37634448
研究概览
Therefore, this study aims to investigate the impact and prognostic significance of CAFs-derived exosomal proteins in ESCC. Despite this, the specific exosomal proteins derived from CAFs and their functions in esophageal squamous cell carcinoma (ESCC) remain unknown.
核心发现
Our findings demonstrate that exosomes derived from CAFs significantly enhance the proliferation, invasion, and migration of esophageal cancer cells.
We identified 842 differentially expressed exosomal proteins through LC-MS/MS analysis, and two key proteins were utilized to establish a risk signature.
Survival analysis revealed a significantly worse prognosis in the high-risk group, with multivariate analysis indicating that the risk score serves as an independent prognostic factor.
Moreover, we observed a significant correlation between the risk score and immune cell infiltration, immunotherapy response, and sensitivity to chemotherapeutic treatments in the study population.
研究设计
Exosomes obtained from CAFs and normal fibroblasts (NFs) were isolated using ultracentrifugation, and the protein expression profiles of the exosomes were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Tumor proliferation was assessed using CCK-8 and colony formation assays, while cell invasion and migration were evaluated using transwell assays.
Lasso regression analysis was employed to establish a signature based on CAFs-derived exosomal proteins using the TCGA database.
Echo Biotech 角色
癌症相关成纤维细胞CAF和正常成纤维细胞NF外泌体分离鉴定及外泌体蛋白质组学测序
关联平台: Exoomics®
关联服务与能力: EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV Proteomics
关联产品或试剂: 无明确产品引用
参考文献
原始论文: Prognostic and immunological role of cancer-associated fibroblasts-derived exosomal protein in esophageal squamous cell carcinoma Int Immunopharmacol. 2023. DOI: 10.1016/j.intimp.2023.110837. PMID/PMCID: 37634448.